Welcome to our dedicated page for Lifemd news (Ticker: LFMD), a resource for investors and traders seeking the latest updates and insights on Lifemd stock.
LifeMD, Inc. (LFMD) operates a leading telehealth platform connecting patients with HIPAA-compliant care solutions. This page serves as the definitive source for verified company news, providing investors and healthcare professionals with timely updates on key developments.
Access consolidated information on earnings reports, strategic partnerships, regulatory milestones, and service expansions. Our curated news collection simplifies tracking LFMD's progress in digital prescription services, remote diagnostics, and integrated telehealth solutions.
Discover updates across three core areas: financial performance announcements, operational developments in WorkSimpli software solutions, and advancements in secure patient-provider communication technologies. All content is sourced from official releases and trusted financial publications.
Bookmark this page for efficient monitoring of LifeMD's innovations in cloud-based pharmacy services, nutritional supplement offerings, and telehealth infrastructure. Return regularly to stay informed about this evolving leader in virtual healthcare delivery.
LifeMD reported a strong first quarter of 2024 with a 33% revenue increase year-over-year to $44.1 million. Telehealth revenue grew by 53% compared to the previous year. The company raised full-year revenue guidance to at least $205 million, showing growth in all business segments. Weight management subscribers surpassed 50,000, with cash-adjusted EBITDA at $4.8 million, a 108% increase. The company generated $5.2 million in cash flow and had a $2.0 million net increase in cash during the quarter.
LifeMD, Inc.® (Nasdaq: LFMD) partners with Withings Health Solutions to enhance virtual patient care for GLP-1 weight-loss patients. By providing advanced in-home health monitoring devices, LifeMD aims to improve patient outcomes through real-time data, drive compliance, and enhance clinical decision-making. This partnership sets a new standard in virtual care, revolutionizing weight management patient care and supporting chronic care management.
LifeMD, Inc. announced the appointment of Dr. Calum MacRae, a renowned clinician and researcher at Harvard Medical School, to its Board of Directors. Dr. MacRae's expertise in cardiology and chronic disease management will enhance the company's virtual primary care services. His track record in implementing innovative solutions and leveraging technology in healthcare is expected to drive LifeMD's growth and improve patient care.
FAQ
What is the current stock price of Lifemd (LFMD)?
What is the market cap of Lifemd (LFMD)?
